Skip links

Raj Vattikuti Named Finalist for Entrepreneur Of The Year 2020 Michigan and Northwest Ohio

Jump To Section

Altimetrik grew by 25% in the first half of 2020, despite the pandemic. Our growth continues to accelerate, fueled by our unique approach to business and digital transformation.
Behind the Mask of GhostSec: Vigilante Hackers on a Cyber Crusade

Altimetrik grew by 25% in the first half of 2020, despite the pandemic. Our growth continues to accelerate, fueled by our unique approach to business and digital transformation. Our teams of practitioners collaborate with our clients, and our incremental approach builds momentum with quick wins that add up to measurable business outcomes.

But our success and our approach are due in large part to our leadership. Which is why we’re thrilled to announce that our own Raj Vattikuti was named one of 29 finalists for Entrepreneur Of The Year 2020 Michigan and Northwest Ohio.

Selected by a panel of independent judges from a competitive pool of nominations, Raj was evaluated based on six criteria, including overcoming adversity; financial performance; societal impact and commitment to building a values-based company; innovation; and talent management.

Raj has excelled at each of the above over his 35-year career, building multiple businesses and leaving a legacy of success and philanthropy. But one of his biggest tests has been the COVID-19 pandemic, which has challenged every entrepreneur in those six areas.

Under Raj’s leadership, Altimetrik has only grown. We were able to go fully remote while maintaining our culture of innovation and never missing a beat with clients. Businesses still had complex, difficult problems to solve, and the need to digitalize became even more urgent in a world suddenly much more reliant on digital services. From our team structure to our Innovation Platform, the pieces were already in place to encourage remote collaboration, generate prototypes and proofs of concept, and continue to deliver for clients.

Across his entire career, Raj has dedicated his talents and his team to achieve measurable business outcomes. As more businesses recognize the need for business and digital transformation or find themselves stuck in the process, Altimetrik has stepped in to drive growth with speed and agility.

Award winners will be announced on Thursday, October 8. Regional award winners are eligible for the Entrepreneur Of The Year National Awards, to be announced in November. The Entrepreneur Of The Year National Overall Award winner will then move on to compete for the EY World Entrepreneur Of The Year Award in June 2021.

Read more about the award and Raj’s thoughts on being a finalist in our press release

Picture of Altimetrik

Altimetrik

Latest Reads

Subscribe

Suggested Reading

Ready to Unlock Your Enterprise's Full Potential?

Vikas Krishan

Chief Digital Business Officer and Head of the EMEA region

Vikas (Vik) Krishan serves as the Chief Digital Business Officer and Head of the EMEA region for Altimetrik. He is responsible for leading and growing the company’s presence across new and existing client relationships within the region.

Vik is a seasoned executive and brings over 25 years of global experience in Financial Services, Digital, Management Consulting, Pre- and Post-deal services and large/ strategic transformational programmes, gained in a variety of senior global leadership roles at firms such as Globant, HCL, Wipro, Logica and EDS and started his career within Investment Banking. He has developed significant cross industry experience across a wide variety of verticals, with a particular focus on working with and advising the C-Suite of Financial Institutions, Private Equity firms and FinTech’s on strategy and growth, operational excellence, performance improvement and digital adoption.

He has served as the engagement lead on multiple global transactions to enable the orchestration of business, technology, and operational change to drive growth and client retention.

Vik, who is based in London, serves as a trustee for the Burma Star Memorial Fund, is a keen photographer and an avid sportsman.

Megan Farrell Herrmanns

Chief Digital Officer, US Central

Megan is a senior business executive with a passion for empowering customers to reach their highest potential. She has depth and breadth of experience working across large enterprise and commercial customers, and across technical and industry domains. With a track record of driving measurable results, she develops trusted relationships with client executives to drive organizational growth, unlock business value, and internalize the use of digital business as a differentiator.

At Altimetrik, Megan is responsible for expanding client relationships and developing new business opportunities in the US Central region. Her focus is on digital business and utilizing her experience to create high growth opportunities for clients. Moreover, she leads the company’s efforts in cultivating and enhancing our partnership with Salesforce, strategically positioning our business to capitalize on new business opportunities.

Prior to Altimetrik, Megan spent 10 years leading Customer Success at Salesforce, helping customers maximize the value of their investments across their technology stack. Prior to Salesforce, Megan spent over 15 years with Accenture, leading large transformational projects for enterprise customers.

Megan earned a Bachelor of Science in Mechanical Engineering from Marquette University. Beyond work, Megan enjoys playing sand volleyball, traveling, watching her kids soccer games, and is actively involved in a philanthropy (Advisory Council for Cradles to Crayons).

Adaptive Clinical Trial Designs: Modify trials based on interim results for faster identification of effective drugs.Identify effective drugs faster with data analytics and machine learning algorithms to analyze interim trial results and modify.
Real-World Evidence (RWE) Integration: Supplement trial data with real-world insights for drug effectiveness and safety.Supplement trial data with real-world insights for drug effectiveness and safety.
Biomarker Identification and Validation: Validate biomarkers predicting treatment response for targeted therapies.Utilize bioinformatics and computational biology to validate biomarkers predicting treatment response for targeted therapies.
Collaborative Clinical Research Networks: Establish networks for better patient recruitment and data sharing.Leverage cloud-based platforms and collaborative software to establish networks for better patient recruitment and data sharing.
Master Protocols and Basket Trials: Evaluate multiple drugs in one trial for efficient drug development.Implement electronic data capture systems and digital platforms to efficiently manage and evaluate multiple drugs or drug combinations within a single trial, enabling more streamlined drug development
Remote and Decentralized Trials: Embrace virtual trials for broader patient participation.Embrace telemedicine, virtual monitoring, and digital health tools to conduct remote and decentralized trials, allowing patients to participate from home and reducing the need for frequent in-person visits
Patient-Centric Trials: Design trials with patient needs in mind for better recruitment and retention.Develop patient-centric mobile apps and web portals that provide trial information, virtual support groups, and patient-reported outcome tracking to enhance patient engagement, recruitment, and retention
Regulatory Engagement and Expedited Review Pathways: Engage regulators early for faster approvals.Utilize digital communication tools to engage regulatory agencies early in the drug development process, enabling faster feedback and exploration of expedited review pathways for accelerated approvals
Companion Diagnostics Development: Develop diagnostics for targeted recruitment and personalized treatment.Implement bioinformatics and genomics technologies to develop companion diagnostics that can identify patient subpopulations likely to benefit from the drug, aiding in targeted recruitment and personalized treatment
Data Standardization and Interoperability: Ensure seamless data exchange among research sites.Utilize interoperable electronic health record systems and health data standards to ensure seamless data exchange among different research sites, promoting efficient data aggregation and analysis
Use of AI and Predictive Analytics: Apply AI for drug candidate identification and data analysis.Leverage AI algorithms and predictive analytics to analyze large datasets, identify potential drug candidates, optimize trial designs, and predict treatment outcomes, accelerating the drug development process
R&D Investments: Improve the drug or expand indicationsUtilize computational modelling and simulation techniques to accelerate drug discovery and optimize drug development processes